Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

Sponsor
Janssen Research & Development, LLC
Study ID
NCT04264884
Status
Approved For Marketing

Eligibility Criteria

Sex
All
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Daratumumab — DRUG
    Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.

Study Details

The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

Key Dates

Status verified
Jul 2020